National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Ataluren (Translarna®)

Ataluren is indicated for the treatment of DMD resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

Rapid Review

Commenced Completed Outcome
18/11/2014 23/12/2014 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
29/10/2015  29/04/2016 Reimbursement Not Recommended


The HSE has approved reimbursement following confidential price negotiations; May 2019